These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10603491)

  • 21. The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use.
    Rothman RB
    Chest; 2000 Nov; 118(5):1516-7. PubMed ID: 11083718
    [No Abstract]   [Full Text] [Related]  

  • 22. Diet medications and valvular heart disease: the current evidence.
    Barasch A; Safford MM
    Spec Care Dentist; 2002; 22(3):108-14. PubMed ID: 12240890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
    Rich S; Rubin L; Walker AM; Schneeweiss S; Abenhaim L
    Chest; 2000 Mar; 117(3):870-4. PubMed ID: 10713017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal effects of fenfluramine-phentermine use.
    Bhattacharyya S; Constantin C; Davar J; Mikhailidis D
    Angiology; 2007 Dec-2008 Jan; 58(6):772-3; author reply 774. PubMed ID: 18216387
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapeutic and adverse actions of serotonin transporter substrates.
    Rothman RB; Baumann MH
    Pharmacol Ther; 2002 Jul; 95(1):73-88. PubMed ID: 12163129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
    Davis R; Faulds D
    Drugs; 1996 Nov; 52(5):696-724. PubMed ID: 9118819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
    Gross SB
    Adv Nurse Pract; 1999 Oct; 7(10):36-40. PubMed ID: 10808770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and the diet pill dilemma.
    Healy BP
    J Womens Health; 1997 Aug; 6(4):391-2. PubMed ID: 9279828
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine.
    McCann UD; Eligulashvili V; Ricaurte GA
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1087-102. PubMed ID: 9829290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension.
    Strother J; Fedullo P; Yi ES; Masliah E
    Arch Pathol Lab Med; 1999 Jun; 123(6):539-40. PubMed ID: 10383810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels.
    Belohlávková S; Simák J; Kokesová A; Hnilicková O; Hampl V
    J Appl Physiol (1985); 2001 Aug; 91(2):755-61. PubMed ID: 11457791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability.
    Curzon G; Gibson EL; Oluyomi AO
    Trends Pharmacol Sci; 1997 Jan; 18(1):21-5. PubMed ID: 9114726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relearning the lessons of history: anorexigens and pulmonary hypertension.
    Langleben D
    Chest; 1998 Jul; 114(1 Suppl):55S-57S. PubMed ID: 9676629
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of dexfenfluramine treatment in rats exposed to acute and chronic hypoxia.
    Eddahibi S; Raffestin B; Launay JM; Sitbon M; Adnot S
    Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1111-9. PubMed ID: 9563727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs; an experimental study in the isolated perfused rat lung, II. Fenfluramine, mazindol, mefenorex, phentermine and R 800.
    Seiler KU; Wassermann O; Wensky H
    Clin Exp Pharmacol Physiol; 1976; 3(4):323-30. PubMed ID: 975621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension.
    Wang HL
    Curr Opin Investig Drugs; 2004 Sep; 5(9):963-6. PubMed ID: 15503652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of selective serotonin reuptake inhibitor therapy on heart valves in patients exposed to benfluorex: a multicentre study.
    Maréchaux S; Jeu A; Jobic Y; Ederhy S; Donal E; Réant P; Abouth S; Arnasteen E; Boulanger J; Ennezat PV; Garban T; Szymanski C; Tribouilloy C
    Arch Cardiovasc Dis; 2013; 106(6-7):349-56. PubMed ID: 23876809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on the pharmacology of serotoninergic appetite-suppressive drugs.
    Garattini S
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 4():S41-8. PubMed ID: 1338385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Scientific and legal issues in fenfluramine/dexfenfluramine litigation.
    Poston WS; Foreyt JP
    Tex Med; 2000 Feb; 96(2):48-56. PubMed ID: 10723254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.
    Teramae CY; Connolly HM; Grogan M; Miller FA
    Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.